In a report released today, Suraj Kalia from Northland Securities maintained a Hold rating on NxStage Medical (NASDAQ: NXTM), with a price target of $30. The company’s shares opened today at $28.15.
According to TipRanks.com, Kalia is a 5-star analyst with an average return of 14.0% and a 60.2% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Obalon Therapeutics Inc, and Apollo Endosurgery Inc.
NxStage Medical has an analyst consensus of Hold, with a price target consensus of $30.
See today’s analyst top recommended stocks >>
The company has a one-year high of $29.39 and a one-year low of $22.70. Currently, NxStage Medical has an average volume of 381.3K.
Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NXTM in relation to earlier this year. Most recently, in May 2018, Joseph Turk, the President of NXTM bought 5,392 shares for a total of $100,237.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
NxStage Medical, Inc. is a medical technology company, which develops, manufactures, and markets products for the treatment of ESRD and acute kidney failure. It operates through the following business segments: System One, In-Center, and Services.
